Early Response to Ketamine for Suicidal Crisis Reduces Suicidal Events at 3 Months
The Journal of Clinical Psychiatry · 2025
DOI: 10.4088/jcp.25m15829 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Clinical Psychiatry, 2025. Verfasst von Martin Pastre und 4 weiteren Autor:innen. Beteiligte Einrichtung: IGF, University of Montpellier, CNRS-INSERM, Montpellier, France. Hauptthemen laut MEDLINE: Ketamine, Suicidal Ideation, Suicide, Attempted. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Intravenous (IV) ketamine has demonstrated rapid reduction of suicidal ideation (SI), but its impact on suicidal attempts remains unclear. This study investigates the effect of IV ketamine on SI at 7 days and suicidal events (suicide attempt or hospitalizations for SI) at 3 months in a real-world clinical setting.
Methods
We conducted an observational retrospective study including 100 adult French patients who received 1 or 2 IV ketamine infusions (0.5 mg/kg) within 1 week for a suicidal crisis between June 2022 and June 2024. Depressive symptoms (Montgomery-Asberg Depression Rating Scale) and SI severity (Columbia-Suicide Severity Rating Scale [C-SSRS]) were assessed at baseline and 7 days postinfusion. Suicidal events were collected from clinical records at 3 months.
Results
Ketamine significantly reduced depressive symptoms (β = -11; P < .001) and SI severity (β = -2.0; P < .001) at 7 days after controlling for age, sex, and number of infusions. A direct (β = -0.78; P < .001) and indirect effect (β = -0.29; P = .007) on SI through depression reduction was observed. Sixty-one percent of patients were SI responders (≥50% reduction in C-SSRS severity). SI responders at 7 days had 75% lower odds of experiencing suicidal events at 3 months (OR =0.25; P = .009).
Conclusion
This is the first study demonstrating that early SI response to IV ketamine is associated with a reduced risk of suicidal events at 3 months. These findings support ketamine's unique antisuicidal properties beyond its antidepressant effects, highlighting its potential role in suicide prevention. Trial Registration: ClinicalTrials.gov identifier: NCT06806475.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- IGF, University of Montpellier, CNRS-INSERM, Montpellier, France.
- Department of Psychiatry, CHU Nimes, Nimes, France.
- Department of Emergency Psychiatry and Post-Acute Care, CHU Montpellier, Montpellier, France.
- Fondation Fondamental, Montpellier, France.
- Corresponding Author: Emilie Olié, MD, PhD, Department of Emergency Psychiatry and Post-acute Care, Academic Hospital, 371 avenue Doyen Gaston Giraud 34295 Montpellier cedex 5, Montpellier, France (e-olie@chu-montpellie…
Zitieren
APA
Pastre, M., Chancel, R., Malestroit, M., Courtet, P., & Olié, E. (2025). Early Response to Ketamine for Suicidal Crisis Reduces Suicidal Events at 3 Months. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.25m15829
Vancouver
Pastre M, Chancel R, Malestroit M, Courtet P, Olié E. Early Response to Ketamine for Suicidal Crisis Reduces Suicidal Events at 3 Months. The Journal of Clinical Psychiatry. 2025. doi:10.4088/jcp.25m15829
BibTeX
@article{Pastre2025,
author = {Pastre, Martin and Chancel, Raphael and Malestroit, Manon and Courtet, Philippe and Olié, Emilie},
title = {Early Response to Ketamine for Suicidal Crisis Reduces Suicidal Events at 3 Months},
journal = {The Journal of Clinical Psychiatry},
year = {2025},
doi = {10.4088/jcp.25m15829}
}
EUVIMED